CordenPharma invests heavily in peptides

CordenPharma is to spend about €900 million over the next three years to expand its peptide technology platform, with investments on both sides of the Atlantic. This will be the largest strategic investment to date for the company, which is owned by pan-European private equity firm Astorg and aims to achieve €1 billion/year in sales from peptides

At CordenPharma Colorado, the former Roche site in Boulder, Colorado, the company will add a new large-scale manufacturing facility and also increase capacity in its existing manufacturing trains. This is a response to increasing demand for glucagon-like peptide 1 agonists for diabetes and obesity, where CordenPharma already has “multiple, long-term, multi-year contracts totalling about €3 billion, with potential upsides”.

In Europe, a new greenfield facility will be built, with the aim of creating additional peptide capacity from early clinical to late-stage commercial manufacturing. On completion, both will be fully integrated within CordenPharma’s network of cGMP manufacturing facilities, along with the dedicated technical and regulatory support.